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Moses Badio1†, Edouard Lhomme2†, Mark Kieh1, Abdoul Habib Beavogui3, Stephen B. Kennedy1,
Seydou Doumbia4, Bailah Leigh5, Samba O. Sow6, Alpha Diallo7, Daniela Fusco7, Matthew Kirchoff8,
Monique Termote2, Renaud Vatrinet9, Deborah Wentworth10, Helène Esperou7, H. Clifford Lane8, Jerome Pierson8,
Deborah Watson-Jones11, Céline Roy2, Eric D’Ortenzio9,12, Brian Greenwood11, Genevieve Chêne2, Laura Richer2,
James D. Neaton10, Yazdan Yazdanpanah9,12* and the PREVAC study teamCorrection to: Trials 22, 86 (2021)
https://doi.org/10.1186/s13063-021-05035-9Following the publication of the original article [1], we
were notified of an error in the affiliation of 3 authors of
the article: Celine Roy, Laura Richert and Genevieve
Chene.
Their affiliation was initially mentioned as: “Partnership
for Research on Ebola Virus in Liberia (PREVAIL),
Monrovia, Liberia”
However, their correct affiliation is: Univ. Bordeaux,
Inserm, Bordeaux Population Health Research Center,
UMR 1219, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN
Clinical Trials Platform, F-33000, Bordeaux, France.tp© The Author(s). 2021 Open Access This artic
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The original article can be found online at https://doi.org/10.1186/s13063-
021-05035-9.
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